Bolt Biotherapeutics' Q4 earnings report showing losses that were less than expected and sales that exceeded estimates is likely to be viewed positively by investors. The improvement over the previous year's performance suggests a positive trend in the company's financial health, which could lead to increased investor confidence and potentially a short-term uptick in the stock price.